Holen Sie sich die Stockscreener-App
30.48
0.42%
-0.13
Handel nachbörslich:
30.65
0.17
+0.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$30.61
Offen:
$30.83
24-Stunden-Volumen:
566.14K
Relative Volume:
0.99
Marktkapitalisierung:
$1.14B
Einnahmen:
$272.30M
Nettoeinkommen (Verlust:
$-5.14M
KGV:
-186.42
EPS:
-0.1635
Netto-Cashflow:
$42.76M
1W Leistung:
-7.83%
1M Leistung:
-21.95%
6M Leistung:
-13.68%
1J Leistung:
-36.14%
1-Tages-Spanne:
$30.15
$30.97
1-Wochen-Bereich:
$30.15
$32.88
52-Wochen-Spanne:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Firmenname
Harrow Inc
Sektor
Telefon
615.733.4731
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
30.48 | 1.24B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | BTIG Research | Buy |
| 2025-06-10 | Eingeleitet | William Blair | Outperform |
| 2025-02-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-04 | Bestätigt | B. Riley Securities | Buy |
| 2024-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2022-09-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-09-24 | Eingeleitet | Aegis Capital | Buy |
| 2021-07-02 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Harrow Inc Aktie (HROW) Neueste Nachrichten
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO - GlobeNewswire
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Insider Confidence In These Growth Stocks For September 2026 - simplywall.st
Harrow Health stock falls 1.55 percent despite Q2 growth - AD HOC NEWS
HROW6348836 Bond Profile: Coupon and Redemption - TradingView
Harrow (HROW) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Harrow, Inc. (HROW) Stock Analysis: Unveiling a 91.63% Potential Upside in the Eyecare Pharmaceutical Sector - DirectorsTalk Interviews
Harrow, Inc. stock gains as market cap nears USD 1.2 billion - AD HOC NEWS
Harrow Health stock holds steady as investors digest recent growth figures - AD HOC NEWS
Harrow Inc. stock dips after valuation signal highlights potential upside - AD HOC NEWS
Is Harrow Inc (HROW) a Bargain After 3.2% Drop? GF Value Says Un - GuruFocus
Is Harrow Inc (HROW) a Bargain After 5.7% Drop? GF Value Says Un - GuruFocus
Harrow at Cantor healthcare conference: long view, bigger eye-care bet - investing.com
HROW Initiates Coverage On Harrow -- Outperform Rating by Leerin - GuruFocus
Andrew R. Boll Assumes Principal Accounting Officer Role at Harrow (NASDAQ: HROW) - Kalkine Media
Harrow Inc. (HROW) Slides 2.96% to $37.4, Approaches Support at $35.53Long Short Pair - dars.gov.et
Andrew R. Boll named Harrow principal accounting officer as Randall E. Pollard departs - TradingView
Harrow, Inc. Announces Management Changes, Effective September 4, 2026 - marketscreener.com
Harrow Health Inc. (HROW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
HROW Q2 2026 Earnings: EPS Misses Estimates as Losses DeepenMid-Term Outlook - vinanet.vn
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Harrow Inc stock gains as analysts see strong revenue growth ahead - ad-hoc-news.de
Harrow Inc (HROW) Stock Up 5.6% and Still Undervalued -- GF Scor - GuruFocus
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Harrow to Participate in Three Investor Conferences in September - GlobeNewswire
Harrow Health Inc. 8.625% Senior Notes due 2026 (HROWL) Peer Comparison – Compare with Others - Value Research
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections - Sahm
Harrow (HROW) Quarterly Results: EPS Falls Short of Its Estimate in the Current Update; Price Move - vinanet.vn
HROW | Harrow, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half - Sahm
Harrow (NASDAQ: HROW) CSO sells 11,250 shares in August option trade - Stock Titan
Harrow (HROW) Outlook: Ends Down by 2.64% at $40.95 for the Current Session; Next Session: Price Remains Between $38.90 Support and $43.00 Resistance on the DayShort Term Trading Ideas - vinanet.vn
What's Going On With Harrow Stock Friday?Harrow (NASDAQ:HROW) - Benzinga
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections - Sahm
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target - Yahoo Finance
In a 50-patient study, Harrow’s eye gel was linked to about 58% less injection discomfort - Stock Titan
Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In? - simplywall.st
Harrow And 2 Other Growth Stocks Insiders Are Betting On - simplywall.st
Harrow CSO Amir Shojaei sells $450,000 in company stock By Investing.com - Investing.com South Africa
Harrow CSO Amir Shojaei sells $450,000 in company stock - Investing.com
Rice Hall James & Associates LLC Takes Position in Harrow, Inc. $HROW - MarketBeat
Will Harrow’s (HROW) TYRVAYA Deal and Reaffirmed 2026 Guidance Redefine Its Dry Eye Strategy? - simplywall.st
Harrow (HROW) Q2 2026 Earnings Call Transcript - The Globe and Mail
Harrow (NASDAQ:HROW) Insider Amir Shojaei Sells 11,250 Shares - MarketBeat
Harrow Inc. (HROW) Slips 1.79% as Shares Test Key Support ZoneLast Point Resistance - vinanet.vn
HROW Q2 2026 Earnings: Wider Loss of $0.34 per Share Misses Estimates by 85.19%, but Stock Rises 2.98 - vinanet.vn
Wall Street Zen Upgrades Harrow (NASDAQ:HROW) to "Hold" - MarketBeat
HC Wainwright Issues Pessimistic Outlook for Harrow Earnings - marketbeat.com
Royce Micro-Cap Fund's Harrow Inc(HROW) Holding History - GuruFocus
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Finanzdaten der Harrow Inc-Aktie (HROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harrow Inc-Aktie (HROW) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Option Exercise |
35.96 |
11,250 |
404,550 |
11,250 |
| Shojaei Amir | CHIEF SCIENTIFIC OFFICER |
Aug 14 '26 |
Sale |
40.00 |
11,250 |
450,000 |
0 |
| Graves Adrienne L | Director |
May 18 '26 |
Buy |
31.07 |
1,000 |
31,070 |
1,000 |
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
1.15%
5.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):